Eli Lilly hands Kumquat Biosciences $70M to kick off cancer drug R&D alliance

Eli Lilly is beginning a research alliance discovering and developing small molecules that stimulate immune responses against cancer. If drugs from the partnership reach the market, Kumquat could earn up to $2 billion in milestone payments.